Clinical Trials Logo

Hodgkin Lymphoma clinical trials

View clinical trials related to Hodgkin Lymphoma.

Filter by:

NCT ID: NCT01351545 Recruiting - Hodgkin Lymphoma Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Start date: October 2011
Phase:
Study type: Observational

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

NCT ID: NCT01333605 Recruiting - Hodgkin Lymphoma Clinical Trials

IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma

Start date: April 2011
Phase: Phase 2
Study type: Interventional

The aim of study is to prove IGEV regimen followed by autologous stem cell transplantation as salvage treatment in patients with refractory or relapsed Hodgkin lymphoma is effective.

NCT ID: NCT01008735 Recruiting - Hodgkin Lymphoma Clinical Trials

Gonadal Toxicity in Women With Hodgkin Lymphoma

FertHD
Start date: July 2009
Phase: N/A
Study type: Observational

The Gruppo Italiano Studio Linfomi has been collecting data on patients with Hodgkin Lymphoma (HL) since 1988. This archive represents a homogeneous series of consecutive patients with HL. The very long follow up and the availability of clinical and treatment data make it feasible to perform a study on the gonadal toxicity related to treatment for HL.

NCT ID: NCT00840047 Recruiting - Neuroblastoma Clinical Trials

Methionine PET/CT Studies In Patients With Cancer

Start date: July 20, 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the usefulness of imaging with radiolabeled methionine in the evaluation of children and young adults with tumor(s). Methionine is a naturally occurring essential amino acid. It is crucial for the formation of proteins. When labeled with carbon-11 (C-11), a radioactive isotope of the naturally occurring carbon-12, the distribution of methionine can be determined noninvasively using a PET (positron emission tomography) camera. C-11 methionine (MET) has been shown valuable in the monitoring of a large number of neoplasms. Since C-11 has a short half life (20 minutes), MET must be produced in a facility very close to its intended use. Thus, it is not widely available and is produced only at select institutions with access to a cyclotron and PET chemistry facility. With the new availability of short lived tracers produced by its PET chemistry unit, St. Jude Children's Research Hospital (St. Jude) is one of only a few facilities with the capabilities and interests to evaluate the utility of PET scanning in the detection of tumors, evaluation of response to therapy, and distinction of residual tumor from scar tissue in patients who have completed therapy. The investigators propose to examine the biodistribution of MET in patients with malignant solid neoplasms, with emphasis on central nervous system (CNS) tumors and sarcomas. This project introduces a new diagnostic test for the noninvasive evaluation of neoplasms in pediatric oncology. Although not the primary purpose of this proposal, the investigators anticipate that MET studies will provide useful clinical information for the management of patients with malignant neoplasms.